Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
The advent of anti-TNF agents as the first approved targeted therapy in the treatment of inflammatory bowel disease (IBD) patients has made a major impact on our existing therapeutic algorithms. They have not only been approved for induction and maintenance treatment in IBD patients, but have also e...
Main Authors: | Raja Atreya, Markus F. Neurath, Britta Siegmund |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00517/full |
Similar Items
-
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
by: Laura Mühl, et al.
Published: (2021-01-01) -
Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy
by: Christian Bojarski, et al.
Published: (2021-07-01) -
Role of the IL23/IL17 Pathway in Crohn’s Disease
by: Heike Schmitt, et al.
Published: (2021-03-01) -
Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?
by: Raja Atreya, et al.
Published: (2022-01-01) -
Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
by: Sebastian Zundler, et al.
Published: (2023-05-01)